2022年华东医药股份有限公司三季报

Stock code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2022-070 Huadong Medicine Co., Ltd. The Third Quarterly Report 2022 The Company and all members of the Board of Directors hereby guarantee that the information presented in this report is authentic, accurate and complete and free of any false records, misleading statements or material omissions. Important Declaration: 1. The Board of Directors, Board of Supervisors, directors, supervisors, and senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this report is authentic, accurate, and complete and free of any false records, misleading statements or material omissions, and shall undertake individual and joint legal liabilities. 2.TheCompany’s legal representativeandtheofficerin chargeofaccounting,andheadof accounting department (accounting supervisor) hereby declare and guarantee that the financial statements in this quarterly report are authentic, accurate, and complete. 3. Has the third quarterly report been audited □ Yes No This report is prepared both in Chinese and English. Should there be any discrepancy between the Chinese and English versions, the Chinese version shall prevail. I. Key financial data (I) Key accounting data and financial indicators Whether the Company needs to perform retroactive adjustment or restatement of previous accounting data □ Yes No Change of the current Change of the first nine The current reporting reporting period over First nine months of months of 2022 over period the same period last 2022 the same period last year year Operating income 9,660,543,088.09 10.43% 27,858,507,079.10 7.45% (yuan) Net profit attributable to listed-company 640,899,562.97 7.71% 1,981,470,047.95 4.54% shareholders (yuan) Net profit attributable to listed-company shareholders after 629,214,050.43 10.77% 1,901,053,230.06 7.89% deducting non- recurring gains/losses (yuan) Net cash flows from operating activities — — 1,320,252,925.99 -37.31% (yuan) Basic earnings per 0.3663 7.71% 1.1324 4.54% share (yuan/share) Diluted earnings per 0.3663 7.71% 1.1324 4.54% share (yuan/share) Weighted average 3.62% -0.13% 11.39% -0.89% return on equity (ROE) End of the current End of last year Change of the end of the current reporting period reporting period over the end of last year Total assets (yuan) 30,662,572,819.67 26,996,403,366.69 13.58% Total ownership interest attributable to 18,068,711,890.05 16,579,374,323.08 8.98% listed-company shareholders (yuan) Share capital of the Company as of the trading day before disclosure: Share capital of the Company as of the trading day before 1,749,809,548.00 disclosure (shares) Fully diluted earnings per share calculated on the basis of the latest share capital Dividends paid on preferred shares 0.00 Perpetual bond interest paid (yuan) 0.00 Fully diluted earnings per share calculated on the basis of the 1.1324 latest share capital (yuan/share) (II) Items and amounts of non-recurring gains/losses Applicable □Inapplicable Unit: RMB yuan Item Amount in the current Amount in the first nine Note reporting period months of 2022 Gains/losses on disposal of non-current assets (including the written-off part of the -6,456,222.42 2,413,541.61 accrued assets impairment reserve) Tax refund and reduction with 298,676.54 2,758,810.47 ultra vires examination and approval or without official approval documents Government grants included in current gains/losses (excluding those closely Mainly due to the related to daily business confirmation of government operation and distributed 34,136,781.84 113,330,078.60 grants by subsidiaries in the constantly in accordance with current period. certain standard quota or quantity in line with national policies and regulations) Other non-operating revenue or expenditure except above- -14,144,513.35 -18,729,257.39 mentioned items Less: Amount affected by 2,614,873.55 17,708,027.55 income tax Amount affected by rights and interests of minority -465,663.48 1,648,327.85 stakeholders (after tax) Total 11,685,512.54 80,416,817.89 -- Details of other items of gains/losses meet the definition of non-recurring gains/losses: □Applicable Inapplicable There are no other gain/loss items in line with the definition of non-recurring gains/losses in the Company. Explanation for recognizing an item listed as a non-recurring gain/loss in the “Interpretative Announcement No. 1 on Information Disclosure Criteria for Public Companies – Non-Recurring Gains/Losses” as a recurring gain/loss □Applicable Inapplicable There is no circumstance in which the Company recognizes an item listed as a non-recurring gain/loss in the “Interpretative AnnouncementNo.1onInformationDisclosureCriteriaforPublicCompanies –Non-RecurringGains/Losses”asarecurringgain/loss. (III) Changes in key accounting data and financial indicators and their reasons Applicable □Inapplicable Balance sheet item End of the period Beginning of the Change Notes on cause of changes period rate Accounts receivable 8,831,060,590.99 6,430,482,175.97 37.33%Mainly due to the increase in payment for goods in the settlement period by the end of the current period Other receivables 371,528,921.48 223,707,267.30 66.08%Mainly due to the increase in receivables and suspense payments in the current period Long-term equity 1,694,315,448.54 984,927,398.68 72.02%Mainly due to investment in Heidelberg Pharma AG investments Other equity instrument 359,700,638.43 257,815,844.68 39.52%Mainly due to investment in Ashvattha Therapeutics investments Other non-current 1,407,052,577.68 911,062,879.83 54.44%Mainly due to the increase in payments for product assets introduction in the current period Short-term 736,186,259.25 1,237,843,228.13 -40.53%Mainly due to the repayment of borrowings in the current borrowing period Notes payable 1,178,537,227.66 671,964,504.00 75.39%Mainly due to the increase in notes for payment in the current period Taxes payable 626,833,981.79 1,029,610,563.41 -39.12%Mainly due to the increase in taxes paid in the current period Non-current Mainlydue to the repayment oflong-term borrowing in the liabilities due within 44,491,162.31 244,256,705.59 -81.79%current period one year Other current 18,254,352.56 11,386,267.11 60.32%Mainly due to the increase of contract liabilities with liabilities corresponding taxes transferred to other current liabilities Long-term 1,312,010,297.75 139,178,905.04 842.68%Mainly due to the increase in new borrowing in the current borrowing period Other comprehensive Mainly due to the decrease in exchange differences arising income -66,798,628.56 -47,768,225.80 -39.84%on conversion of financial statements denominated in foreign currencies Income statement Amount of the Amount of the Change Cause of change item current period previous period Investment income -99,173,464.90 -60,001,493.40 -65.28%Mainly due to the decrease in investment income from associates Gains on assets 5,578,009.76 -149,966.61 3819.50%Mainly due to the sale of real properties in the current disposal